| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |